Chris Reutelingsperger

Professor

Prof. Chris Reutelingsperger studied Biochemistry at the University of Utrecht. As a PhD student, he discovered and patented the anticoagulant annexin A5 (VAscular Anticoagulant) and defended the thesis 'Vascular anticoagulant, a novel anticoagulant mechanism' at Maastricht University in 1987. He was awarded the five-year Senior Fellowship of the Royal Dutch Academy of Sciences (KNAW) and spent part of his post-doc time at the Boehringer Ingelheim Institute für Arzneimittelforschung in Vienna, to work on elucidating the genetic code of annexin A5.

In 1994, he discovered and patented the power of annexin A5 to detect apoptotic cells. In 1992, he received a tenure track at the Department of Biochemistry of Maastricht University, resulting in a tenured position as Associate Professor in 1997. In 2009, he was appointed Professor of Biochemistry of Apoptosis at Maastricht University. He (co-)authored over 200 peer reviewed papers (H-index 68, source Scholar Google). He is (co-)inventor of 12 granted patents and CSO of PharmaTarget, a biotech company which he co-founded in 2006. He was President of the 8th International Conference on Annexins in 2015. Currently, he chairs the Scientific Advisory Board of Matisse Pharmaceuticals (Netherlands), a biotech company developing therapeutic drugs to treat sepsis.

Chris Reutelingsperger's research activities address molecular and cellular mechanisms of vascular remodeling, vasculitis, atherosclerosis and vascular calcification. His interests focus on vascular calcification, cell death programs, phagocytosis, complement, vitamin K-dependent proteins and annexins, with emphasis on annexins A1 and A5. His major experimental approach utilises in vitrocell biology an in-house developed integrated in vitro assay platform (The BioHybrid, 'organ on-a-chip') covering all major vascular cell types and processes in the pathophysiology of vascular diseases. His strategy encompasses linking basic research to clinical application by establishing collaborations with clinical research and with industry.

Department of Biochemistry
Universiteitssingel 50, 6229 ER Maastricht
PO Box 616, 6200 MD Maastricht
Room number: H4.354
T: +31(0)43 388 16 74

  • 2021
    • Sangani, N. B., Gomes, A. R., Curfs, L. M. G., & Reutelingsperger, C. P. (2021). The role of Extracellular Vesicles during CNS development. Progress in Neurobiology, 205, [102124]. https://doi.org/10.1016/j.pneurobio.2021.102124
    • Huckriede, J., de Vries, F., Hultstroem, M., Wichapong, K., Reutelingsperger, C., Lipcsey, M., de Frutos, P. G., Frithiof, R., & Nicolaes, G. A. F. (2021). Histone H3 Cleavage in Severe COVID-19 ICU Patients. Frontiers in Cellular and Infection Microbiology, 11, [694186]. https://doi.org/10.3389/fcimb.2021.694186
    • Huckriede, J., Anderberg, S. B., Morales, A., de Vries, F., Hultstrom, M., Bergqvist, A., Ortiz-Perez, J. T., Sels, J. W., Wichapong, K., Lipcsey, M., van de Poll, M., Larsson, A., Luther, T., Reutelingsperger, C., Garcia de Frutos, P., Frithiof, R., & Nicolaes, G. A. F. (2021). Evolution of NETosis markers and DAMPs have prognostic value in critically ill COVID-19 patients. Scientific Reports, 11(1), [15701]. https://doi.org/10.1038/s41598-021-95209-x
    • Jaminon, A. M. G., Akbulut, A. C., Rapp, N., Kramann, R., Biessen, E. A. L., Temmerman, L., Mees, B., Brandenburg, V., Dzhanaev, R., Jahnen-Dechent, W., Floege, J., Uitto, J., Reutelingsperger, C. P., & Schurgers, L. J. (2021). Development of the BioHybrid Assay: Combining Primary Human Vascular Smooth Muscle Cells and Blood to Measure Vascular Calcification Propensity. Cells, 10(8), [2097]. https://doi.org/10.3390/cells10082097
    • Liu, X., Arfman, T., Wichapong, K., Reutelingsperger, C. P. M., Voorberg, J., & Nicolaes, G. A. F. (2021). PAD4 takes charge during neutrophil activation: Impact of PAD4 mediated NET formation on immune-mediated disease. Journal of Thrombosis and Haemostasis, 19(7), 1607-1617. https://doi.org/10.1111/jth.15313
    • Ercig, B., Gomes Graca, N. A., Kangro, K., Arfman, T., Wichapong, K., Hrdinova, J., Kaijen, P., van Alphen, F., van den Biggelaar, M., Vanhoorelbeke, K., Veyradier, A., Coppo, P., Reutelingsperger, C., Nicolaes, G. A. F., Männik, A., & Voorberg, J. (2021). N-glycan mediated shielding of ADAMTS13 prevents binding of pathogenic autoantibodies in immune-mediated TTP. Blood, 137(19), 2694-2698. https://doi.org/10.1182/blood.2020007972
    • Liu, X., Wichapong, K., Lamers, S., Reutelingsperger, C. P. M., & Nicolaes, G. A. F. (2021). Autocitrullination of PAD4 does not alter its enzymatic activity: In vitro and in silico studies. International Journal of Biochemistry & Cell Biology, 134, 105938. [105938]. https://doi.org/10.1016/j.biocel.2021.105938
    • van Gorp, R. H., Dijkgraaf, I., Bröker, V., Bauwens, M., Leenders, P., Jennen, D., Dweck, M. R., Bucerius, J., Briedé, J. J., van Ryn, J., Brandenburg, V., Mottaghy, F., Spronk, H. M. H., Reutelingsperger, C. P., & Schurgers, L. J. (2021). Off-target effects of oral anticoagulants - vascular effects of vitamin K antagonist and non-vitamin K antagonist oral anticoagulant dabigatran etexilate. Journal of Thrombosis and Haemostasis, 19(5), 1348-1363. https://doi.org/10.1111/jth.15289
    • van Kuijk, K., Demandt, J. A. F., Perales-Patón, J., Theelen, T. L., Kuppe, C., Marsch, E., de Bruijn, J., Jin, H., Gijbels, M. J., Matic, L., Mees, B. M. E., Reutelingsperger, C. P. M., Hedin, U., Biessen, E. A. L., Carmeliet, P., Baker, A. H., Kramann, R. K., Schurgers, L. J., Saez-Rodriguez, J., & Sluimer, J. C. (2021). Deficiency of myeloid PHD proteins aggravates atherogenesis via macrophage apoptosis and paracrine fibrotic signalling. Cardiovascular Research. https://doi.org/10.1093/cvr/cvab152
    • Timmermans, S. A. M. E. G., Damoiseaux, J. G. M. C., Werion, A., Reutelingsperger, C. P., Morelle, J., & van Paassen, P. (2021). Functional and Genetic Landscape of Complement Dysregulation Along the Spectrum of Thrombotic Microangiopathy and its Potential Implications on Clinical Outcomes. Kidney International Reports, 6(4), 1099-1109. https://doi.org/10.1016/j.ekir.2021.01.034